The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase III study of nivolumab and ipilimumab versus carboplatin-based doublet in first-line treatment of PS 2 or elderly (≥ 70 years) patients with advanced non–small cell lung cancer (Energy-GFPC 06-2015 study).
 
Herve Lena
Honoraria - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD Oncology; Pfizer; Sandoz; Takeda
Consulting or Advisory Role - AstraZeneca/MedImmune; Daiichi Sankyo/Lilly; Novartis; Pfizer; Roche/Genentech; Sanofi; Takeda
 
Isabelle Monnet
Travel, Accommodations, Expenses - oxyvie; Pfizer; Takeda
 
Olivier Bylicki
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb/Celgene; MSD; Roche; Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; MSD
 
Clarisse Audigier-Valette
Honoraria - Abbvie; Amgen; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Pfizer; Roche; Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Janssen Oncology; Lilly; MSD; Pfizer; Roche; Takeda
 
Lionel Falchero
No Relationships to Disclose
 
Alain Vergnenegre
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Roche
Research Funding - AstraZeneca/MedImmune (Inst); Roche (Inst); Roche (Inst)
 
Pierre Demontrond
No Relationships to Disclose
 
Laurent Greillier
Honoraria - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Roche; Takeda
Travel, Accommodations, Expenses - BMS; Boehringer Ingelheim; MSD; Roche
 
Margaux Geier
Consulting or Advisory Role - Bristol-Myers Squibb; Chugai Pharma; Pfizer; Sanofi
 
Florian Guisier
Honoraria - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; MSD; Pfizer; Roche; Takeda
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Pfizer
 
Chantal Decroisette
Consulting or Advisory Role - AstraZeneca; BMS; MSD Oncology; Roche; Takeda
Travel, Accommodations, Expenses - Roche; Takeda
 
Chrystele Locher
No Relationships to Disclose
 
Romain Corre
Honoraria - AstraZeneca/MedImmune; Bristol Myers Squibb; MSD Oncology
Consulting or Advisory Role - AstraZeneca; Sanofi; Takeda
 
Claire Cropet
No Relationships to Disclose
 
Christos Chouaid
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; MSD; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Roche
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Pfizer; Roche
 
Charles Ricordel
Consulting or Advisory Role - AstraZeneca/MedImmune; BMS; Takeda; Takeda